Dr. Behfar Ehdaie

So we were able to determine the eligibility criteria in one meeting and discuss what's the next steps. And I think what we didn't realize in the other parole is that we were trying to write a trial like you see every other trial written, which is off the bat, millions of dollars, lots of eligibility criteria, lots of exclusionary criteria, triple checks and double checks for every step.

So we were able to determine the eligibility criteria in one meeting and discuss what's the next steps. And I think what we didn't realize in the other parole is that we were trying to write a trial like you see every other trial written, which is off the bat, millions of dollars, lots of eligibility criteria, lots of exclusionary criteria, triple checks and double checks for every step.

So we were able to determine the eligibility criteria in one meeting and discuss what's the next steps. And I think what we didn't realize in the other parole is that we were trying to write a trial like you see every other trial written, which is off the bat, millions of dollars, lots of eligibility criteria, lots of exclusionary criteria, triple checks and double checks for every step.

And that turned out to be something that was eye-opening. This trial that we started in 2014 and 2015 that ended in 2018 or 2019 cost over $3 million to put together to enroll only 101 patients. Obviously, that's not feasible for many investigator-initiated trials.

And that turned out to be something that was eye-opening. This trial that we started in 2014 and 2015 that ended in 2018 or 2019 cost over $3 million to put together to enroll only 101 patients. Obviously, that's not feasible for many investigator-initiated trials.

And that turned out to be something that was eye-opening. This trial that we started in 2014 and 2015 that ended in 2018 or 2019 cost over $3 million to put together to enroll only 101 patients. Obviously, that's not feasible for many investigator-initiated trials.

So I realized early on that these trials that are outside of clinical practice, meaning we have separate assessments of quality of life, we need research study assistance in every step of the way, patients are not going through the same pathways as our straight clinic pathway to be enrolled and consented and the trial discussed wouldn't be feasible unless we do one of these trials maybe in our lifetime.

So I realized early on that these trials that are outside of clinical practice, meaning we have separate assessments of quality of life, we need research study assistance in every step of the way, patients are not going through the same pathways as our straight clinic pathway to be enrolled and consented and the trial discussed wouldn't be feasible unless we do one of these trials maybe in our lifetime.

So I realized early on that these trials that are outside of clinical practice, meaning we have separate assessments of quality of life, we need research study assistance in every step of the way, patients are not going through the same pathways as our straight clinic pathway to be enrolled and consented and the trial discussed wouldn't be feasible unless we do one of these trials maybe in our lifetime.

for each individual clinician who's interested in trials. And that's when going through this trial and subsequent trials, I realized our trials need to be integrated in many ways to our clinical practice.

for each individual clinician who's interested in trials. And that's when going through this trial and subsequent trials, I realized our trials need to be integrated in many ways to our clinical practice.

for each individual clinician who's interested in trials. And that's when going through this trial and subsequent trials, I realized our trials need to be integrated in many ways to our clinical practice.

And this was a pioneering concept that was championed early by Andrew Vickers and Peter Scardino, who were able to upfront tell us what the outcomes we measure in trials are often the outcomes we measure in our clinical practice. So if we want to look at radical prostatectomy outcomes, we want to look at biochemical occurrence, positive surgical margins, sexual function, urinary function.

And this was a pioneering concept that was championed early by Andrew Vickers and Peter Scardino, who were able to upfront tell us what the outcomes we measure in trials are often the outcomes we measure in our clinical practice. So if we want to look at radical prostatectomy outcomes, we want to look at biochemical occurrence, positive surgical margins, sexual function, urinary function.

And this was a pioneering concept that was championed early by Andrew Vickers and Peter Scardino, who were able to upfront tell us what the outcomes we measure in trials are often the outcomes we measure in our clinical practice. So if we want to look at radical prostatectomy outcomes, we want to look at biochemical occurrence, positive surgical margins, sexual function, urinary function.

And why not, in every modification that occurs in the operating room that surgeons do every day, Why not just record that, randomize patients or the surgeons, and look at those outcomes as we would anyways without the need of research study assistance or other factors that really make the complexity of clinical trials very expensive?

And why not, in every modification that occurs in the operating room that surgeons do every day, Why not just record that, randomize patients or the surgeons, and look at those outcomes as we would anyways without the need of research study assistance or other factors that really make the complexity of clinical trials very expensive?

And why not, in every modification that occurs in the operating room that surgeons do every day, Why not just record that, randomize patients or the surgeons, and look at those outcomes as we would anyways without the need of research study assistance or other factors that really make the complexity of clinical trials very expensive?

Yeah, so as we think about clinically integrated trials, our outcome measures need to be something we record as part of clinical care. Nothing separate. Our eligibility criteria should be very similar to the patients we treat every day. In this specific trial that you're speaking about, which was our umbrella trial and modification of radical prostatectomy, You're right.

Yeah, so as we think about clinically integrated trials, our outcome measures need to be something we record as part of clinical care. Nothing separate. Our eligibility criteria should be very similar to the patients we treat every day. In this specific trial that you're speaking about, which was our umbrella trial and modification of radical prostatectomy, You're right.